Clinical Trials

Carcinoma, Hepatocellular

NCT05358691 2025-04-16

A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

Lung Neoplasms

NCT04889066 2024-12-20

Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases

Carcinoma, Non-Small-Cell Lung

NCT03802747 2024-12-09

Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases

Colorectal Neoplasms

NCT05718297 2024-10-08

BOUNCE

Carcinoma, Non-Small-Cell Lung

NCT05757843 2024-09-19

Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab

Carcinoma, Non-Small-Cell Lung

NCT04944173 2024-09-03

SCION

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm, Residual

NCT05572476 2024-06-05

LURBIMUNE

Small Cell Lung Carcinoma

NCT05209529 2024-02-23

Chemo-free BRCA-targeted Neoadjuvant Strategy

Breast

Triple Negative Breast Neoplasms

NCT05848843 2024-01-23

A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

Lung Neoplasms

NCT05161533 2023-10-18

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

Lung Neoplasms

NCT03982173 2023-01-26

MATILDA

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05383001 2022-09-27

Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

Carcinoma, Non-Small-Cell Lung

NCT04001413 2022-07-29

Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients

Head & Neck

Oropharyngeal Neoplasms

NCT03319316 2022-01-10

SOLUTION

Phase EARLY_PHASE1 Withdrawn

Squamous Non-small Cell Lung Cancer

NCT04223648 2021-11-22

Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

Dermatologic

Melanoma

NCT03673735 2021-05-10

ADHERE

Phase 3 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04262375 2020-11-17

DOMINATION

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT04262388 2020-11-17

DOME

Phase EARLY_PHASE1 Withdrawn

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT04088032 2020-07-16

Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer

BreastOther neoplasm

Breast Cancer Female

NCT04073160 2020-07-07

TRIO Bladder

Genitourinary

Urinary Bladder Neoplasms

NCT04184518 2020-06-02

CEDUVEAL-M

Dermatologic

Uveal Melanoma, Neoplasm Metastasis

NCT02885727 2019-09-12

Panc-Durval+RT

Pancreatic Neoplasms

NCT02871323 2019-08-20

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Myeloid

Polycythemia Vera, Primary Myelofibrosis

NCT03419559 2019-04-16

Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT02868632 2019-04-05

Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

Pancreatic Neoplasms

NCT03241017 2018-04-09

IDA-D

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03004105 2018-03-16

MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

Phase EARLY_PHASE1 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT03235869 2018-03-15

Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT02966587 2018-01-17

Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Microsatellite Instability

NCT02993991 2017-12-29

PRIMED-001

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02673814 2016-08-01

Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer